18:11 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

AmpliPhi reports data from expanded access program for bacteriophages

AmpliPhi Biosciences Corp. (NYSE-M:APHB) reported data from seven patients with serious, life-threatening infections who did not respond to antibiotics from an expanded access program showing that AB-SA01 or AB-PA01 (Biophage-PR, AmpliPhage-001) in combination with best...
19:50 , Aug 3, 2017 |  BC Innovations  |  Strategy

FDA's phage philosophy

Against a backdrop of doubt about the regulators’ outlook for bacteriophage therapeutics, FDA is assuring drug developers the re-emerging modality is firmly on the table. The position should assuage at least some concerns in a...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Biophage Pharma Inc, Phagelux deal

Phagelux’s Phagelux Canada Inc. subsidiary will purchase IP and phage and bacterial libraries from Biophage for $200,000 in cash and $550,000 in equity up front. Biophage is also eligible for milestones of up to $250,000...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

AmpliPhi BioSciences preclinical data

In a mouse model of acute P. aeruginosa infection, BioPhage-PR reduced viral load after 6 hours vs. ciprofloxacin-treated mice. All mice survived at 24 hours post-infection and BioPhage-PR and ciprofloxacin each led to an about...
07:00 , May 28, 2007 |  BC Week In Review  |  Company News

Biophage scientific advisory board update

Biophage Pharma Inc. (TSX:BUG), Montreal, Quebec   Business: Infectious, Inflammation, Veterinary   Appointed: Maximilien Arella, professor of virology at the Institut Armand Frappier at the University of Quebec  ...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Biophage management update

Biophage Pharma Inc. (TSX:BUG), Montreal, Quebec   Business: Infectious, Inflammation, Veterinary   Hired: Louis Guindon as CFO and treasurer, formerly VP of corporate development at 20-20 Technologies Inc.; he replaces interim CFO Myer Bentob, who...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Company News

a2sp Ltd., Biophage sales and marketing update

a2sp will combine its Magic Tag immobilization technology with BUG's Biophage biosensor platform to reduce problems associated with non-specific binding of phages to surfaces such as magnetic beads. a2sp Ltd. , Warwick, U.K.   Biophage...
08:00 , Oct 31, 2005 |  BC Week In Review  |  Company News

Biophage management update

Biophage Pharma Inc. (TSX-V:BUG), Montreal, Quebec   Business: Infectious, Inflammation, Veterinary   Hired: Myer Bentob as treasurer and CFO, while remaining chairman and CEO at Montec Holdings Inc.  ...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Biophage board of directors update

Biophage Pharma Inc. (TSE:BUG), Montreal, Quebec   Business: Infectious, Inflammation, Veterinary   Appointed: Pearl Chin, managing director at Seraphima Ventures; she replaces Bruce Schmidt, who departed  ...
07:00 , Oct 3, 2005 |  BC Week In Review  |  Company News

Biophage, Integrated Environment Technologies Ltd. sales and marketing update

The companies will jointly market BUG's PDS Biosensor, which detects low levels of live bacteria, and IEVM's EcaFlo equipment, which produces biocides. Biophage Pharma Inc. (TSE:BUG), Montreal, Quebec   Integrated Environment Technologies Ltd. (IEVM), Little...